ArticleBMJ open2022

Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.

Yue Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.